Patent application number | Description | Published |
20080207610 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION - Disclosed are novel isoflavone derivatives having the structure of Formula I | 08-28-2008 |
20080318983 | A2B ADENOSINE RECEPTOR ANTAGONISTS - Disclosed are methods for treating asthma, inflammatory gastrointestinal tract disorders, cancer, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis using A | 12-25-2008 |
20090054457 | SUBSTITUTED HETEROCYCLIC COMPOUNDS - Disclosed are novel substituted heterocyclic derivatives having the structure of Formula I: | 02-26-2009 |
20090137520 | A1 ADENOSINE RECEPTOR AGONISTS - Disclosed are novel compounds that are A | 05-28-2009 |
20090137802 | A2B ADENOSINE RECEPTOR ANTAGONISTS - Disclosed are processes for the synthesis of novel compounds that are A | 05-28-2009 |
20090156544 | A1 ADENOSINE RECEPTOR AGONISTS - Disclosed are novel compounds that are partial and full A | 06-18-2009 |
20090209533 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION - Disclosed are novel isoflavone derivatives having the structure of Formula I | 08-20-2009 |
20090247557 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS - Disclosed are novel compounds a compound of Formula I | 10-01-2009 |
20090325896 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS - Disclosed are novel compounds that are partial and full A | 12-31-2009 |
20100056538 | Pro-drugs of A2B Adenosine Receptor Antagonists - Disclosed are prodrugs of A | 03-04-2010 |
20100113449 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (IA) or (IB): | 05-06-2010 |
20100210579 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS - Disclosed are novel compounds a compound of Formula I | 08-19-2010 |
20100222300 | A2B Adenosine Receptor Antagonists - Disclosed are novel compounds that are A | 09-02-2010 |
20110021521 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: | 01-27-2011 |
20110130362 | A2B ADENOSINE RECEPTOR ANTAGONISTS - Disclosed are novel compounds that are A | 06-02-2011 |
20110160162 | PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS - Disclosed are prodrugs of A | 06-30-2011 |
20110257127 | A2B ADENOSINE RECEPTOR ANTAGONISTS - Disclosed are novel compounds that are A | 10-20-2011 |
20110257387 | PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS - Disclosed is a synthesis suitable for large scale manufacture of an A | 10-20-2011 |
20120165350 | PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS - Disclosed is a synthesis suitable for large scale manufacture of an A | 06-28-2012 |
20120289493 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: | 11-15-2012 |
20130005706 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: | 01-03-2013 |
20130012492 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: | 01-10-2013 |
20130123280 | A2B ADENOSINE RECEPTOR ANTAGONISTS - Disclosed are novel compounds that are A | 05-16-2013 |
20130184255 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: | 07-18-2013 |
20140135317 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: | 05-15-2014 |
20140213539 | PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS - Disclosed is a synthesis suitable for large scale manufacture of an A | 07-31-2014 |
20140303158 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: | 10-09-2014 |